Cargando…
Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease
BACKGROUND: Obesity is a risk factor for non-alcoholic fatty liver disease (NAFLD), although obese patients with NAFLD do not always develop significant fibrosis. The distribution of body fat could predict the risk of NAFLD progression. AIM: To investigate the role of bioelectrical impedance-estima...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673970/ https://www.ncbi.nlm.nih.gov/pubmed/33268953 http://dx.doi.org/10.3748/wjg.v26.i42.6658 |
_version_ | 1783611425485225984 |
---|---|
author | Hernández-Conde, Marta Llop, Elba Fernández Carrillo, Carlos Tormo, Beatriz Abad, Javier Rodriguez, Luis Perelló, Christie López Gomez, Marta Martínez-Porras, José Luis Fernández Puga, Natalia Trapero-Marugan, Maria Fraga, Enrique Ferre Aracil, Carlos Calleja Panero, José Luis |
author_facet | Hernández-Conde, Marta Llop, Elba Fernández Carrillo, Carlos Tormo, Beatriz Abad, Javier Rodriguez, Luis Perelló, Christie López Gomez, Marta Martínez-Porras, José Luis Fernández Puga, Natalia Trapero-Marugan, Maria Fraga, Enrique Ferre Aracil, Carlos Calleja Panero, José Luis |
author_sort | Hernández-Conde, Marta |
collection | PubMed |
description | BACKGROUND: Obesity is a risk factor for non-alcoholic fatty liver disease (NAFLD), although obese patients with NAFLD do not always develop significant fibrosis. The distribution of body fat could predict the risk of NAFLD progression. AIM: To investigate the role of bioelectrical impedance-estimated visceral fat (VF) in assessing NAFLD severity. METHODS: In this cross-sectional study, patients with biopsy-proven NAFLD were prospectively included. All patients underwent anthropometric evaluation, blood tests and bioelectrical impedance analysis. RESULTS: Between 2017 and 2020, 119 patients were included [66.4% male, 56 years (SD 10.7), 62.2% obese, 61.3% with metabolic syndrome]. Sixty of them (50.4%) showed significant fibrosis (≥ F2) in liver biopsy. Age, VF and metabolic syndrome were associated with significant fibrosis (61 years vs 52 years, 16.4 vs 13.1, 73.3% vs 49.2%, respectively; P < 0.001 for all). In the multivariate analysis, VF and age were independently associated with significant fibrosis (VF, OR: 1.11, 95%CI: 1.02-1.22, P = 0.02; age, OR: 1.08, 95%CI: 1.03-1.12, P < 0.01). A model including these variables showed and area under the receiver operating characteristic curve (AUROC) of 0.75, which was not inferior to transient elastography or NAFLD fibrosis score AUROCs. We developed a nomogram including age and VF for assessing significant fibrosis in routine practice. CONCLUSION: VF is a surrogate marker of liver fibrosis in patients with NAFLD. Bioelectrical impedance analysis is an inexpensive and simple method that can be combined with age to guide patient referral when other resources may be unavailable. |
format | Online Article Text |
id | pubmed-7673970 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-76739702020-12-01 Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease Hernández-Conde, Marta Llop, Elba Fernández Carrillo, Carlos Tormo, Beatriz Abad, Javier Rodriguez, Luis Perelló, Christie López Gomez, Marta Martínez-Porras, José Luis Fernández Puga, Natalia Trapero-Marugan, Maria Fraga, Enrique Ferre Aracil, Carlos Calleja Panero, José Luis World J Gastroenterol Observational Study BACKGROUND: Obesity is a risk factor for non-alcoholic fatty liver disease (NAFLD), although obese patients with NAFLD do not always develop significant fibrosis. The distribution of body fat could predict the risk of NAFLD progression. AIM: To investigate the role of bioelectrical impedance-estimated visceral fat (VF) in assessing NAFLD severity. METHODS: In this cross-sectional study, patients with biopsy-proven NAFLD were prospectively included. All patients underwent anthropometric evaluation, blood tests and bioelectrical impedance analysis. RESULTS: Between 2017 and 2020, 119 patients were included [66.4% male, 56 years (SD 10.7), 62.2% obese, 61.3% with metabolic syndrome]. Sixty of them (50.4%) showed significant fibrosis (≥ F2) in liver biopsy. Age, VF and metabolic syndrome were associated with significant fibrosis (61 years vs 52 years, 16.4 vs 13.1, 73.3% vs 49.2%, respectively; P < 0.001 for all). In the multivariate analysis, VF and age were independently associated with significant fibrosis (VF, OR: 1.11, 95%CI: 1.02-1.22, P = 0.02; age, OR: 1.08, 95%CI: 1.03-1.12, P < 0.01). A model including these variables showed and area under the receiver operating characteristic curve (AUROC) of 0.75, which was not inferior to transient elastography or NAFLD fibrosis score AUROCs. We developed a nomogram including age and VF for assessing significant fibrosis in routine practice. CONCLUSION: VF is a surrogate marker of liver fibrosis in patients with NAFLD. Bioelectrical impedance analysis is an inexpensive and simple method that can be combined with age to guide patient referral when other resources may be unavailable. Baishideng Publishing Group Inc 2020-11-14 2020-11-14 /pmc/articles/PMC7673970/ /pubmed/33268953 http://dx.doi.org/10.3748/wjg.v26.i42.6658 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Observational Study Hernández-Conde, Marta Llop, Elba Fernández Carrillo, Carlos Tormo, Beatriz Abad, Javier Rodriguez, Luis Perelló, Christie López Gomez, Marta Martínez-Porras, José Luis Fernández Puga, Natalia Trapero-Marugan, Maria Fraga, Enrique Ferre Aracil, Carlos Calleja Panero, José Luis Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease |
title | Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease |
title_full | Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease |
title_fullStr | Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease |
title_full_unstemmed | Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease |
title_short | Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease |
title_sort | estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease |
topic | Observational Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673970/ https://www.ncbi.nlm.nih.gov/pubmed/33268953 http://dx.doi.org/10.3748/wjg.v26.i42.6658 |
work_keys_str_mv | AT hernandezcondemarta estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease AT llopelba estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease AT fernandezcarrillocarlos estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease AT tormobeatriz estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease AT abadjavier estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease AT rodriguezluis estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease AT perellochristie estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease AT lopezgomezmarta estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease AT martinezporrasjoseluis estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease AT fernandezpuganatalia estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease AT traperomaruganmaria estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease AT fragaenrique estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease AT ferrearacilcarlos estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease AT callejapanerojoseluis estimationofvisceralfatisusefulforthediagnosisofsignificantfibrosisinpatientswithnonalcoholicfattyliverdisease |